Rationale: Among individuals with Chronic Obstructive Pulmonary Disease (COPD), depression is one of the most common yet under-recognized and under-treated comorbidities. Although depression has been associated with reduced adherence to maintenance medications used in other conditions, such as diabetes, little research has assessed depression's role in COPD medication use and adherence.
Chronic Obstructive Pulmonary Disease (COPD) is a chronic lower respiratory disease characterized by obstruction of airflow. COPD is a leading cause of morbidity and mortality worldwide, and the third leading cause of death in the US. 1, 2 Although smoking is the most common risk factor for the development of COPD in the US, environmental exposures and genetics also play a role. 1, 3 In 2010, medical costs of COPD in the US were estimated at $36 billion and projected to reach $49 billion by 2020. 4 Clinicians select pharmacologic strategies utilized for the management of COPD based on COPD severity to reduce symptoms and prevent COPD exacerbations. 1 Maintenance medications, including inhaled corticosteroids (ICS), long-acting β-agonists (LABAs), and longacting anticholinergics (LAAC) have been shown to reduce exacerbations and improve lung function and health-related quality of life among moderate to severe patients. [5] [6] [7] Nonetheless, use of and adherence to COPD maintenance medications remains low, ranging from 29%-56%, and contributes to increased hospitalization, healthcare costs, and mortality. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Among patients with COPD, depression remains one of the most common, yet least recognized and under-treated, co-morbidities, with a prevalence of 17% -44%. [21] [22] [23] [24] [25] [26] [27] Depression has been associated with decreased adherence to maintenance medications used in chronic conditions such as diabetes. 28, 29 Few studies have assessed the association between depression and adherence to COPD medications, and these were limited by a cross-sectional study design. 30, 31 The objective of this study was to assess the impact of depression on COPD maintenance medication adherence among a nationally representative sample of Medicare beneficiaries newly diagnosed with COPD. We hypothesize that new episodes of depression will result in decreased adherence to COPD maintenance medications.
Methods

Study Population
We 32 We required continuous Medicare Parts A, B, D, and no Part C coverage for 24 months following initial diagnosis of COPD (index date) during the study period to ensure adequate follow-up. All
Medicare beneficiaries who met criteria for COPD since 1999 have the date of first diagnosis of COPD reported in the CMS Master Beneficiary Summary File (MBSF). We used this date to exclude beneficiaries whose first diagnosis of COPD occurred prior to the study period (2006) (2007) (2008) (2009) (2010) (2011) (2012) . We required that study participants have at least two prescription fills of a maintenance medication during the 24 month follow-up period.
Exposure
We used ICD-9-CM codes 296.2x, 296.3x, and 311.xx to define depression. These codes have been used previously and exclude bipolar disorder, schizoaffective disorder, and dysthymic disorder. [33] [34] [35] Presence of depression was defined as at least one diagnosis code on at least one inpatient claim or at least two outpatient claims during the study period. To increase identification of beneficiaries with depression, we also accepted evidence of at least one antidepressant prescription fill in conjunction with diagnosis of depression on one outpatient claim. Information on antidepressant fills was collected from Part D prescription drug event files.
Depression is a chronic disorder that occurs as one or more unique episodes and could be diagnosed at any time during the study period. 36, 37 We were interested in how new episodes of depression impacted adherence to COPD maintenance medications. Therefore, among individuals with depression episodes both pre-and post-COPD diagnosis, we defined a new episode of depression post-COPD diagnosis as one occurring more than 5 months after the depression episode pre-COPD diagnosis.
Outcome
The primary outcome of this study was adherence to inhaled COPD maintenance medications.
We searched for all inhaled maintenance medications (ICS, LABA, LAAC) in the Part D prescription drug events file. We excluded oral methylxanthines because they can be used as either acute or maintenance medications and are limited to severe COPD. 37 We divided followup time post-COPD index date into 30-day months, and measured adherence using proportion of days covered (PDC) (number of daily doses in the prescription/30) for all maintenance medications per month. The PDC ranges from 0 to 1. PDC is a widely used measure of medication adherence in administrative claims data. 38, 39 Adherence was measured monthly from the date of the first fill of a COPD maintenance medication following COPD diagnosis through the end of the study period. We created a rolling 3-month average adherence to reduce variability in monthly adherence measures. Because distribution of this variable was highly skewed, we created adherence categories: <0.2, ≥0.2 to <0.4, ≥0.4 to < 0.6, ≥0.6 to <0.8, and ≥0.8.
Covariates
Baseline comorbidities at COPD diagnosis were determined using CCW's 27 flagged comorbid conditions. 41 If the date of first diagnosis of a chronic condition was prior to the date of COPD diagnosis, the patient was considered to have that chronic condition at baseline. We controlled for diagnosis of asthma (ICD-9-CM codes 493.xx on one or more inpatient claims or two or more outpatient claims). We summed indicator variables for chronic conditions including Alzheimer's disease and related dementias, atrial fibrillation, chronic kidney disease, heart failure, diabetes, ischemic heart disease, osteoarthritis, stroke, and asthma to create a comorbidity measure. Our measure had a range of 0-9 and was categorized as <2, 2-3, and >3 chronic conditions based on its distribution. We created time-varying comorbidity diagnoses for use in our regression model by comparing the first date of diagnosis with the first day of each month following diagnosis of COPD.
Depression is one of the CCW's 27 flagged comorbid conditions. The CCW algorithm differs from our definition by including ICD-9-CM codes 296.5x, 296.6x, 296.89, 298.0, 300.4, and 309.1. We used the CCW depression algorithm to capture individuals with a history of depression prior to 2006.
To assess severity of depression, we created a variable comprising a count of three measures obtained from inpatient and outpatient claims: the presence of a "4" in the fifth place of an ICD-9-CM code for depression; evidence of psychotherapy or other non-pharmacological treatment; and psychiatric hospitalization with a primary diagnosis of depression. This variable had a range of 0-3 and was dichotomized at 1.
We created a variable indicating any use of short acting beta-agonists and short acting anticholinergics (COPD acute medications) during the month. We searched for the presence of any nursing home claim on any inpatient stay, or healthcare common procedure coding system (HCPCS) or Place of Service codes on a skilled nursing facility (SNF) claim during the month to indicate nursing home stay within the month.
Characteristics suggestive of COPD severity included supplemental oxygen use, COPDrelated hospitalization (dichotomized at ≥ 1 COPD hospital days/month), and monthly COPDrelated emergency department (ED) visits (dichotomized at ≥ 1 ED visit/month). 30, 42, 43 We searched carrier and durable medical equipment claims for the following preventive health services utilization measures: influenza vaccination, colorectal cancer screening, prostate cancer screening, and mammography and Papanicolaou smears. 44 An annual count of preventive health services utilization measures (including mammography or Papanicolaou test) was created as an indicator of healthy behavior. This variable had a range of 0-3 and, based on its distribution, was dichotomized at one or more.
We linked our Medicare cohort to county-level data from the Area Health Resource File (AHRF). The AHRF contains health resources and socioeconomic indicators from multiple sources. We abstracted variables representing median household income, percent of persons aged 25 and older with 4 or more years of college, percent of persons aged 25 and older with less than a high school education, and number of primary care providers/100,000 population.
Data Analysis
Distributions of variables were examined overall and by depression status. For descriptive purposes, we made comparisons between beneficiaries diagnosed with depression at any time during the 24-month follow-up and those who were not, using chi-square or Student's t tests as appropriate. We plotted the average three month adherence to COPD maintenance medications over time.
We used generalized estimating equations with a multinomial distribution and a cumulative logit link to model the odds of being in a higher adherence category (greater adherence) as a function of our time-varying depression variable and assumed a compound symmetry covariance matrix to estimate the correlations among measurements within an individual. The analyses were conducted at the person-month level. We tested interactions with sex, age and low-income subsidy a priori. Covariates associated with depression or adherence were considered for inclusion in our model. Comorbidities, acute inhaler use, COPD severity variables, our preventive health measure, and nursing home residence were allowed to vary with time. Covariates resulting in greater than a 10% change to the effect estimate or whose Type III p-value was <0.001 were included in the final model. Odds ratios (OR) and 95%
confidence intervals (CI) were reported.
To test the assumption of proportionality in our multinomial model, we conducted sensitivity analyses. We created dichotomous variables representing three month average adherence at each decile between 0-1. We used generalized estimating equations with a binomial distribution and a logit link to model the odds of an observation falling into the higher adherence category and assumed a compound symmetry covariance matrix to estimate the correlations among measurements within an individual. We ran separate models for each decile. Sensitivity analyses included all variables from the final regression model of the main analysis. Average monthly adherence to COPD maintenance medications was low, with a peak of 0.57 in the month following the first fill and decreasing rapidly before plateauing at 0.35 by the seventh month ( Figure 1 ). Individuals with depression had lower adherence throughout the study period compared to those without depression. Only 20% of depressed individuals and 22% of non-depressed individuals fell into the highest (>80%) adherence category.
Our adjusted multinomial regression model contained terms for new episode depression, time, COPD index year, age, sex, race, region, percent of county-level population without a high school diploma, original reason for Medicare entitlement, low-income subsidy, comorbid conditions, acute inhaler use, COPD severity variables, preventive health measures, nursing home residence within the month, and polypharmacy. There was no effect modification by sex, age, or low-income subsidy.
In our adjusted model, a new episode of depression was associated with decreased odds of greater adherence to COPD maintenance medications (OR 0.93; 95% CI 0.89, 0.98)( The association between depression and decreased adherence to COPD medications has been previously reported 31, 42, 43, 45 ; however, only a single study quantified the effect. 30 Qian et al. (2014) analyzed maintenance medication adherence using a cross-sectional study design among Medicare beneficiaries with COPD and reported that individuals with depression were 11% less likely to have high adherence. 30 Our study overcame the limitations of the crosssectional study design by examining the longitudinal association between depression and medication adherence, yet reported results consistent with those of the Qian study (9% less likely to have greater adherence).
Comorbid depression in COPD resulted in decreased adherence, as did the presence of any other comorbid condition (except asthma), suggesting that multimorbidity decreases adherence, possibly through complex medication regimens or patient prioritization of one comorbid illness over another. 46 Our results suggest that individuals with more than three chronic conditions are at highest risk of poor adherence. This effect was mitigated by increased severity of COPD symptoms, evidenced by acute inhaler, oxygen use, and COPD-related hospitalizations, and is consistent with a prior report. 30 Historically, use of and adherence to COPD maintenance medications has been suboptimal, with many individuals with COPD not receiving any maintenance medications. 14, 15, 17 Among individuals who use COPD medications, adherence is low, which poses difficulties in medication management. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In this study, we found only 22% of the sample achieved adherence of ≥ 80%, regardless of depression status. Our study was conducted among beneficiaries with at least two medication fills over the 24 months post-COPD diagnosis, representing those most likely to adhere to COPD medications, as they have documented primary adherence by picking up their COPD medication prescriptions.
Nonetheless, the observed drop in adherence following first COPD maintenance medication fill suggests most individuals with COPD are not using medications as prescribed. Although a prior study by Qian et al. reported adherence of ≥ 80% in 36% of Medicare beneficiaries with COPD, it did not assess adherence among newly-diagnosed COPD cases and evaluated adherence from first-filled to last-filled prescription, differences that could account for our lower adherence rate. 30 Women were less likely to be adherent to COPD maintenance medications compared to men, which is consistent with two prior studies conducted among individuals with COPD.
30,47
Other studies have not reported a significant association between sex and adherence to COPD medications or medications generally. 11, 20, 45, 48 In our study, women comprised 65% of the study sample, and 75% of those with depression; hence, residual confounding by depression status is possible. Race was associated with decreased adherence to COPD medications, which is consistent with Qian and colleague's study conducted among Medicare beneficiaries with COPD.
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Limitations and Strengths
As with any study, ours has limitations which should be noted. Our study includes Medicare beneficiaries diagnosed with depression; however, depression is underdiagnosed in administrative claims data. 49 This potential mis-classification of exposure would cause our results to be biased toward the null. In addition, we likely underestimated the burden of depression in COPD by excluding dysthymic disorder and depression found in bipolar and schizoaffective disorder from our depression definition. Furthermore, our adherence measure was based on prescription fills and does not measure actual use of inhaled medications. Finally, we could not control for all confounding or direct influences of medication adherence. For example, future work may consider evaluating the impact of other medications, such as oral corticosteroids, which can mimic psychiatric side-effects.
As well, this study has notable strengths. This study is the first to assess adherence to COPD maintenance medications among Medicare beneficiaries newly diagnosed with COPD.
Additionally, we used a longitudinal study design to capture episodes of diagnosed depression, b Includes Alzheimer's disease and related dementias, atrial fibrillation, chronic kidney disease, heart failure, diabetes, ischemic heart disease, osteoarthritis, stroke, and asthma 
